Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance

ABBOTT LABORATORIES

2022-Q3 EPS reported $3.32 revenue$33,562,000,000

Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.
Raises FY2022 adjusted EPS guidance to $5.17-$5.23; GAAP guidance $3.75-$3.81.
U.S. Medical Devices sales +11.3%; FreeStyle Libre revenues ~$1.0B in Q3.
COVID testing-related sales $1.7B in Q3 vs $1.9B a year ago; full-year outlook $7.8B.
Restarted infant formula production at Sturgis plant; quarterly dividend $0.47/share payable Nov. 15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.